SCIENTURE HOLDINGS, INC. Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments
SCIENTURE HOLDINGS, INC. (SCNX) reported Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments of -$16.56 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-02.
Discontinued › Income Statement › Other Income
us-gaap:CostmethodInvestmentsRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2018-03-02
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-12-31 was $0.00.
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-09-30 was -$5.04K.
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-06-30 was -$11.51K.
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-03-31 was $0.00.
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for fiscal 2017 was -$16.56K.
- SCIENTURE HOLDINGS, INC. cost-method investments, realized gain (loss), excluding other than temporary impairments for fiscal 2016 was -$37.58K.
| Period end | Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments 3 month | Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments 6 month | Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments 9 month | Cost-method Investments, Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | -$5.04K derived: sum of 2 quarters · filed 2018-03-02 | -$16.56K derived: sum of 3 quarters · filed 2018-03-02 | -$16.56K 10-K · filed 2018-03-02 |
| 2017-09-30 | -$5.04K 10-Q · filed 2017-11-07 | -$16.56K derived: sum of 2 quarters · filed 2017-11-07 | -$16.56K 10-Q · filed 2017-11-07 | -$16.56K derived: sum of 4 quarters · filed 2018-03-02 |
| 2017-06-30 | -$11.51K 10-Q · filed 2017-08-04 | -$11.51K 10-Q · filed 2017-08-04 | -$11.51K derived: sum of 3 quarters · filed 2018-03-02 | -$11.51K derived: sum of 4 quarters · filed 2018-03-02 |
| 2017-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2018-03-02 | $0.00 derived: sum of 2 quarters · filed 2018-03-02 | $0.00 derived: sum of 3 quarters · filed 2018-03-02 | -$37.58K derived: sum of 4 quarters · filed 2018-03-02 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $0.00 derived: sum of 2 quarters · filed 2018-03-02 | -$37.58K derived: sum of 3 quarters · filed 2018-03-02 | -$37.58K 10-K · filed 2018-03-02 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | -$37.58K derived: sum of 2 quarters · filed 2017-11-07 | -$37.58K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | -$37.58K 10-Q · filed 2017-08-04 | -$37.58K 10-Q · filed 2017-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |